The appointment of a former Roche executive as the firm's new COO is viewed as a significant event for a firm still in the early stages of driving adoption of its Pheno system.
The firm experienced a 30 percent jump in sales of immunoassays, attributed in part to a $6.2 million increase in influenza revenues year-over-year.
NantHealth's net loss fell by 37 percent, to $14.7 million, as revenue from software-related revenue jumped by 23 percent while expenses fell.
The company reported sales of 3,129 OVA1 tests in the quarter, up 66 percent from 1,884 tests in the year-ago quarter.
The Gaithersburg, Maryland-based company continues to await US Food and Drug Administration clearance for its antimicrobial resistance test.
LineaRx was formed last year to commercialize Applied DNA Sciences' technologies for DNA design, manufacture, and chemical modification by large scale PCR.
Quanterix intends to grant underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock at the public offering price.
The company beat analyst estimates on the top and bottom line, driven by sales of its Panorama noninvasive prenatal and Horizon carrier screening tests.
The firm received a notice from Nasdaq on August 2 saying its stock had not met the $1-per-share closing bid price requirement for 30 consecutive business days.
The company attributed the revenue decline to a 96 percent drop in licensing revenues, which more than offset a 36 percent increase in product sales.
The test will be used to identify which metastatic, castration-resistant prostate cancer patients harbor germline BRCA mutations and will likely benefit from Lynparza.
The point-of-care diagnostics firm tallied $9.6 million in revenues in the second quarter, besting analysts' consensus estimate of $8.8 million.
Revenues from product and product-related services more than doubled to $4.4 million, but collaborative development revenues sank 52 percent to $1.4 million.
The firm said revenues fell because of delayed shipments of HIV self-tests and ongoing softness in the consumer genomics markets.
The San Francisco-based medical genetics firm generated $53.5 million in revenues in the second quarter, beating analysts' consensus estimate of $50.7 million.
The company sold nearly twice as many tests as in Q2 last year, with clinical test revenue more than doubling and total revenue reaching $54 million for the quarter.
Expedeon will supply Sona Nanotech with colloidal gold technology for use in the development of multiplex lateral flow assays.
Oxford Immunotec beat analysts' consensus estimates on the top and bottom lines as its second quarter net loss last year swung to a profit this year.
The CMS ruling follows the release of data showing strong performance of the test, including its ability to detect bloodstream pathogens missed by blood culture.
The firm noted that in the quarter, the US Food and Drug Administration granted Breakthrough Device designation for its exosome-based liquid biopsy test.
Revenues were in line with Wall Street estimates, and revenue growth represented strength across all three of the firm's business segments.
Driving the revenue increase was a 187 percent year-over-year rise in the number of billable tests the company delivered during the quarter.
The company posted Q2 revenues of $13.5 million, up from $8.6 million in Q2 2018 and above the consensus Wall Street estimate of $11.5 million.
The Carlsbad, California-based molecular diagnostics firms reported $18.4 million in revenues, up from 14.9 million in Q2 of 2018.
The German firm has developed a PCR technology that rapidly regulates temperature with so-called microcyclers diffused in the master mix solution.